Long Term Survival of Patient with Late-Stage Non-Small Cell Carcinoma of Lung: A Case Report
Lung cancer is the most common cause of cancer death with limited survival. Most of the lung cancer cases are non-small cell variety, and most of the patients are in an advanced stage. After histopathological diagnosis, the next step is documenting the presence of actionable mutations like EGFR. When positive, EGFR portends sensitivity of the tumour to EGFR TKIs and a better prognosis. We report a case of advanced NSCLC with protracted survival of almost 10 years from the diagnosis of metastatic disease. The patient presented with progressions multiple times but was found non-compliant with Erlotinib. Compliance was reinforced every time, followed by the response on surveillance..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
International Journal of Medical Reviews and Case Reports - 6(2022), 13, Seite 36-38 |
| Sprache: |
Englisch ; Portugiesisch |
|---|
| Beteiligte Personen: |
Saif ur Rab [VerfasserIn] |
|---|
| Links: |
dx.doi.org [kostenfrei] |
|---|
| Themen: |
Epidermal growth factor receptor |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ008895201 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ008895201 | ||
| 003 | DE-627 | ||
| 005 | 20230503113208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ008895201 | ||
| 035 | |a (DE-599)DOAJ6c33f637626841f49c4b5f61e03e92db | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a por | ||
| 100 | 0 | |a Saif ur Rab |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long Term Survival of Patient with Late-Stage Non-Small Cell Carcinoma of Lung: A Case Report |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Lung cancer is the most common cause of cancer death with limited survival. Most of the lung cancer cases are non-small cell variety, and most of the patients are in an advanced stage. After histopathological diagnosis, the next step is documenting the presence of actionable mutations like EGFR. When positive, EGFR portends sensitivity of the tumour to EGFR TKIs and a better prognosis. We report a case of advanced NSCLC with protracted survival of almost 10 years from the diagnosis of metastatic disease. The patient presented with progressions multiple times but was found non-compliant with Erlotinib. Compliance was reinforced every time, followed by the response on surveillance. | ||
| 650 | 4 | |a non-small cell lung cancer | |
| 650 | 4 | |a epidermal growth factor receptor | |
| 650 | 4 | |a erlotinib | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Mussadique Ali Jhatial |e verfasserin |4 aut | |
| 700 | 0 | |a Umm e Kalsoom Awan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Medical Reviews and Case Reports |d International Sci Ink Press Ltd, 2018 |g 6(2022), 13, Seite 36-38 |w (DE-627)DOAJ000092606 |x 25349821 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2022 |g number:13 |g pages:36-38 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5455/IJMRCR.172-1615181365 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/6c33f637626841f49c4b5f61e03e92db |z kostenfrei |
| 856 | 4 | 0 | |u https://mdpub.net/index.php?fulltxt=62099&fulltxtj=172&fulltxtp=172-1615181365.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2534-9821 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2022 |e 13 |h 36-38 | ||